Recent randomized clinical trials (RCT) comparing anastrozole (Arimidex) and letrozole (Femara) to tamoxifen in the first-line treatment of postmenopausal women with advanced hormonesensitive breast cancer have demonstrated that both agents were at least as effective as tamoxifen. In addition, one RCT has revealed significant superiority of letrozole to tamoxifen with regard to tumor response rate and time to progression. Based on the efficacy and toxicity data, anastrozole or letrozole may replace tamoxifen. A cost effectiveness analysis was undertaken to determine whether the new agents are economically acceptable alternatives to tamoxifen. In the absence of a randomized three-arm trial, a decision model was developed to simulate and compare the most common therapeutic outcomes. The clinical data were obtained from a meta analysis of modern (i.e., post-1990) randomized trials. Clinical outcomes data from the various trials were statistically pooled using a random effects model to provide point estimates and 95% confidence intervals. Total hospital resource consumption was collected from the charts of 87 patients with advanced disease who had failed tamoxifen therapy. The model suggested a comparable duration of quality-adjusted progression-free survival between letrozole and anastrozole, both being superior to tamoxifen (179 days vs. 172 days vs. 161 days). Letrozole and anastrozole had overall costs of Can$2,883 and $2,847 per patient, respectively, which were marginally higher than tamoxifen at $Can2,258 per patient. When the costs and benefits were combined, the data generated an incremental cost per qualityadjusted progression-free year of $12,500 and $19,600 for letrozole and anastrozole, respectively, relative to tamoxifen. Letrozole and anastrozole are both economically acceptable alternatives to tamoxifen in the first-line treatment setting. However, when efficacy and cost effectiveness are considered together, letrozole could be preferentially considered.
For the past 3 decades, tamoxifen has been the standard first-line hormonal agent in patients with breast cancer with advanced disease who are positive for estrogen (ER)/progesterone (PR) receptors. 1 There have been several attempts to replace tamoxifen with selective aromatase inhibitors as the treatment standard in the first-line setting. 2 However, randomized trials comparing tamoxifen to either formestane or fadrozole failed to demonstrate superiority in terms of time to progression (TTP) and overall response. [3] [4] [5] Three randomized trials involving the third generation selective aromatase inhibitors, anastrozole and letrozole, have now been completed. Two large randomized clinical trials powered for equivalence comparing anastrozole to tamoxifen in the first-line hormonal treatment of advanced breast cancer have recently been published. 6, 7 In the larger European study, 668 postmenopausal patients with locally advanced or metastatic breast cancer were randomized in a one-to-one ratio to receive tamoxifen 20 mg or anastrozole 1 mg daily in a double-blinded fashion. 6 The trial was designed and powered to demonstrate equivalence with respect to TTP and overall response. Patients randomized to the anastrozole treatment had a comparable overall response relative to tamoxifen (32.9% vs. 32.6%; p ϭ NS). Similarly, the median TTP was similar between the anastrozole and tamoxifen group (8.2 vs. 8.3 months; p ϭ NS). Both agents were well tolerated, but thromboembolic events and vaginal bleeding were reported more frequently in patients treated with tamoxifen. The smaller U.S. trial that enrolled 353 patients was also able to demonstrate equivalence between anastrozole and tamoxifen. 7 A large double-blind superiority study has also been published by the International Letrozole Breast Cancer Group. 8 In this trial, 907 patients with advanced breast cancer were randomized to receive tamoxifen 20 mg or letrozole 2.5 mg on a daily basis until disease progression or patient dropout. Patient groups were well balanced with respect to age, ER/PR receptor status, and prior exposure to adjuvant tamoxifen. Patients randomized to letrozole had superior overall tumor response From the Ontario Cancer Institute/Princess Margaret Hospital, Ottawa Regional Cancer Centre and Toronto Sunnybrook Regional Cancer Centre, Ontario Canada.
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(30% vs. 20%; p ϭ 0.0006) and TTP (9.4 vs. 6.0 months; p ϭ 0.001).
Response and progression-free survival are considered meaningful outcomes in patients with advanced breast cancer. Given the findings of these three large randomized trials, it appears that anastrozole and letrozole should now be considered viable alternatives to tamoxifen in the first-line setting. However, in many countries, including Canada, anastrozole and letrozole are substantially more expensive on an acquisition cost basis than tamoxifen. Therefore, the issues that drug formulary committees have to consider are twofold: 1) Does anastrozole or letrozole provide good economic value relative to tamoxifen when all the clinical and economic factors are quantified? and 2) Is one agent more cost effective than another as an alternative to tamoxifen in the firstline hormonal treatment of advanced breast cancer. In this study, a cost-utility analysis was conducted to determine whether the approved third-generation aromatase inhibitors are economically attractive alternatives to tamoxifen from the perspective of the publicly funded Canadian healthcare system.
METHODS

Development of Decision Model
To simulate the comparison of the third generation aromatase inhibitors to tamoxifen in the setting of first-line hormonal therapy in postmenopausal women, a decision model was developed. The baseline analysis considered postmenopausal women with ER/PR-positive breast cancer who are anthracycline naïve and have not received first-line hormonal therapy in the advanced setting. The primary clinical outcome for measuring successful therapy in the current analysis was quality-adjusted progression-free survival benefit. The face and content validity of the model was verified by two oncologists (S.H. and M.T.) involved in the management of patients with breast cancer in Ontario.
The model began at the decision node (square) where a choice would have to be made between letrozole, anastrozole, and tamoxifen (Fig. 1) . Patients would receive letrozole 2.5 mg, anastrozole 1 mg, or tamoxifen 20 mg on a daily basis. After a 3-month treatment period, the probability of response (circle) would be assessed for each of the three agents. Patients responding to first-line hormonal therapy would continue treatment until disease progression. In contrast, patients with disease progression at the 3-month interval would be offered standard chemotherapy consisting of a combination of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC). As an alternative to the baseline analysis, for patients who had previously received an anthracycline-based regimen in the adjuvant setting and had experienced disease progression, singleagent paclitaxel or docetaxel were considered in the model.
Following three cycles of chemotherapy, nonresponders would then be offered palliative therapy while responders would continue to receive an additional three cycles of FAC (Fig. 1 ). For patients with non-life-threatening disease, a second hormonal agent may be an option prior to chemotherapy (e.g., aromatase inhibitors 3 tamoxifen). Since randomized crossover trials revealed that response rates for these sequences were comparable at approximately 10%, 9 second-line crossover therapy was not considered because the final results would be unaffected.
Clinical Data
The clinical data required for the model, which consisted of disease response, side effect rates, and progression-free survival estimates for each of the three hormonal alternatives, were obtained from a meta analysis of modern (post-1990) randomized trials. A computer literature search of Medline, Cancer Lit, and the Cochrane databases was performed from 1990 through 2001 for human clinical studies involving letrozole, anastrozole, and tamoxifen. Eligibility criteria relative to validity of trial design and analysis were used to identify potential studies. To be eligible, studies must have been published in a peer-reviewed journal; used a randomized design with letrozole 2.5 mg daily, anastrozole 1 mg daily, or tamoxifen 20 mg daily in one of the treatment arms; and subjects must have been postmenopausal women with either positive or unknown ER/PR status and had not received tamoxifen as a first-line treatment in the advanced setting. A similar set of study inclusion criteria was used to identify randomized trials for first-line FAC and taxane chemotherapy after anthracycline failures. During the literature review, effort was given to avoid the inclusion of duplicate publications.
Studies were selected on the basis of the inclusion criteria. The following data were abstracted from accepted studies: drugs, dose, frequency of administration, definition of response, study design (e.g., blinded vs. non-blinded), eligibility criteria, study populations, incidence of drug-related toxicity, number of withdrawals caused by adverse drug reactions, and all clinical outcomes. Response and adverse effect rates from the different studies were combined using a random effects model to calculate a point estimate and 95% confidence intervals for each outcome. 10 In the case of the reported estimates for median progression-free survival, equal weighting was used with studies of similar sample sizes.
Estimation of Treatment Costs
The analytic time period for this investigation was from the start of first-line hormonal therapy until disease progression, and a Canadian healthcare system perspective was taken. In a previous but recent pharmacoeconomic evaluation of anastrozole and letrozole in the second-line setting, Dranitsaris et al. 11 conducted a retrospective chart review to measure chemotherapy treatment costs in patients who failed second-line hormonal therapy. The chemotherapy protocols evaluated consisted of FAC, paclitaxel and docetaxel. Since chemotherapy costs would be the same regardless of when treatment was initiated (i.e., after a first-line or second-line failure to hormonal therapy), it was considered acceptable to use these costs in the current decision analysis.
Patient data obtained from the charts included demographic information, hormone receptor status, radiation history, and previous anticancer therapy. Hospital resource consumption associated with anticancer therapy was then collected. This consisted of costs for hospitalization, outpatient clinic visits, antiemetics (e.g., ondansetron), chemotherapy (including preparation and administration), laboratory tests, patient monitoring, adverse effect management, and all related physicians fees. All patient costs were captured from the first cycle up to 3 weeks after the last cycle of chemotherapy. Resource utilization during the progression-free survival interval included costs for physician visits and monitoring. 
Quality of Life Data
In the original study by Dranitsaris et al., anastrozole and letrozole were evaluated in the second-line setting. Healthrelated quality of life values were measured in terms of patient preferences for alternative treatment outcomes. Quality-adjusted progression-free periods were measured as "healthy months equivalent" for the time spent in each outcome of the decision model using the Time Trade-Off technique. 12 The scores in months were then converted to utility measures between 0 and 1, where 0 represented death and 1 was a state of optimal quality of life. As previously described, 11 the utility assessments were obtained from a random 25 Canadian women living in Ontario, Canada.
The health states evaluated consisted of letrozole and anastrozole disease responses and failures that were then followed by chemotherapy. Health state utilities for tamoxifen were not evaluated in the original study. Since the large randomized trials reported that the aromatase inhibitors and tamoxifen were comparably well tolerated, 6 -8 the assumption made was that health state utilities between these two classes of drugs would be identical.
Cost Utility Analysis
The clinical, economic, and respondent preference data were then combined in a cost-utility analysis comparing the two aromatase inhibitors to tamoxifen. The primary outcome determined in the study was the incremental cost per qualityadjusted progression-free year gained, which was calculated by dividing the difference in cost relative to tamoxifen (numerator) by the difference in quality-adjusted progression-free survival benefit (denominator). The stability of the baseline results was then tested by a comprehensive sensitivity analysis. This procedure included substituting paclitaxel and docetaxel in place of FAC chemotherapy, and reanalyzing the data using the upper and lower 95% confidence limits of response and chemotherapy costs.
RESULTS
Meta Analysis of Randomized Trials
Seven randomized trials with first-line anastrozole, letrozole, or tamoxifen in one of the treatment arms met the study inclusion criteria. These trials provided a total of nine treatment arms for statistical pooling (anastrozole ϭ 2, letrozole ϭ 1, and tamoxifen ϭ 6). There were six trials published in peer-reviewed journals (Table 1) . [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The six tamoxifen trials had used 20 mg daily. Similarly, there were seven comparative studies with first-line FAC chemotherapy: four with docetaxel and three trials with paclitaxel ( Table 1) .
The outcomes of the statistical pooling of clinical data with first-line hormonal therapy generated an overall objective response of 29.0% (95% CI: 25% to 33%) for anastrozole, 30.0% (95% CI: 26% to 35%) for letrozole, and 24.2% (95% CI: 18.6% to 29.7%) for tamoxifen, respectively (Fig. 2) . The associated progression-free survival was approximately 255 days for anastrozole, 287 days for letrozole, and 214 days for tamoxifen (Table 1) . These data were subsequently used in the model. For FAC chemotherapy, the pooled response was 52.1% (95% CI: 46.7% to 57.5%), whereas rates for paclitaxel and docetaxel were 22.5% (95% CI: 15.5% to 29.5%) and 37.2% (95% CI: 28.6% to 45.8%), respectively (Table 1) .
Economic Data from the Chart Review
In the original study, 11 87 patients who received chemotherapy between 1997 to mid-1999 met the inclusion criteria for chart review. Twenty-four patients received first-line FAC chemotherapy. For second-line taxane administration, 34 received paclitaxel and 29 docetaxel (Table 2) . Most patient's tumors were ER/PR positive, with a small proportion having an unknown receptor status. All patients had disease progression during tamoxifen prior to receiving chemotherapy. Patients received a median of five cycles of FAC and four cycles of paclitaxel or docetaxel at standard doses ( Table 2 ). The total cost of FAC was approximately $627 per cycle, whereas second-line paclitaxel and docetaxel were $1,680 and $2,653 per cycle (Table 3) .
Quality of Life Data for the Model
Utility values associated with the use of aromatase inhibitors from public female volunteers are presented in Table 4 . In both groups of respondents, utility scores were lowest under the scenarios where patients failed hormonal therapy and subsequent chemotherapy. The health state with the highest utility score (i.e., highest quality of life) was when a response to hormonal therapy was achieved. Both groups considered this health state to be equivalent to approximately 0.80 on a quality of life scale between 0 and 1 ( Table 4) .
With these data and the meta analysis results, the model was used to estimate the quality-adjusted progression-free survival for each strategy. With the utilities from public volunteers, the aromatase inhibitors provided a modest benefit over tamoxifen, but the differences between letrozole and anastrozole were within 7 days of each other (Table 5) . Therefore, the differences between the aromatase inhibitors were too small to conclude than one agent provided more quality-adjusted benefit than another.
Cost Utilities Analysis
The utility values were then combined with the clinical and economic data for the cost-utility analysis. The average cost per patient for anastrozole and letrozole was $2,847 and $2,883 compared to $2,258 for tamoxifen, respectively (Table 6 ). Despite their substantially higher drug acquisition cost, letrozole and anastrozole had overall costs that were marginally higher than tamoxifen while providing greater quality-adjusted survival benefits. These findings were primarily due to the higher overall tumor response rate and progression-free survival benefit with the aromatase inhibitors (Table 1) . Hence, the main economic driver behind this outcome was that a smaller number of patients treated with letrozole and anastrozole would require chemotherapy over the time periods evaluated by the model.
The next exercise was to estimate the average cost per quality-adjusted progression-free year. This was accomplished by dividing the average overall cost of each agent by the model estimated quality-adjusted progression-free survival benefit (Table 6 ). The results indicated comparable cost effectiveness ratios between tamoxifen ($5,100) and letrozole ($5,900) with anastrozole ($6,100) being the least economically favorable of the three agents. The final analysis was to estimate the incremental cost per quality-adjusted progression-free year gained when using letrozole or anastrozole as alternatives to tamoxifen. This was accomplished by dividing the difference in overall cost relative to tamoxifen by the difference in utility values. Letrozole had a slight economic advantage over anastrozole ($12,500 vs. $19,600), suggesting better value for limited healthcare resources. Notwithstanding, both of these estimates are below the $20,000 threshold, which has been suggested as a marker for "good economic value" for new medical technologies.
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Sensitivity Analysis
A series of one-way sensitivity analyses were then conducted, characterized by substituting the cost of paclitaxel and docetaxel in place of FAC and using the 95% CI limits for response rates and FAC chemotherapy costs. All the comparisons were relative to tamoxifen only since no "head-to-head" comparative trial between the aromatase inhibitors has been reported to date. Given the higher cost of taxane chemotherapy (Table 3) , there was an improvement in the cost effectiveness of letrozole and anastrozole, with letrozole providing the greatest improvement in economic value (Table 7) . In all the other scenarios evaluated, letrozole remained the pre- ferred alternative to tamoxifen, with modest but consistent economic advantages over anastrozole (Table 7) .
DISCUSSION
In the past few years, there have been several important advances in hormonal therapy directed at the management of postmenopausal women with advanced breast cancer. The new selective aromatase inhibitors, which include letrozole, anastrozole, and exemestane, are more effective than megestrol acetate in patients whose disease progressed on tamoxifen. 2, 30 The success of these trials inspired additional studies against tamoxifen, the current first-line standard in the advanced disease setting.
Two equivalence trials comparing anastrozole to tamoxifen were conducted, one in North America (n ϭ 353) and a large one (n ϭ 668) in Europe. 7, 8 Both studies demonstrated that anastrozole was clinically equivalent to tamoxifen in terms of overall clinical response and TTP. In the smaller North American study, a retrospective analysis determined that patients randomized to the anastrozole group had a longer median TTP than those treated with tamoxifen (11.1 vs. 5.6 months). However, when the data from both of these equivalence trials were combined, the superiority analysis of the pooled data failed to show significant differences in overall tumor response and TTP. 31 In contrast to the equivalence study design adopted for anastrozole, a large (n ϭ 907) doubleblind randomized superiority trial comparing letrozole to tamoxifen was recently reported. Letrozole was found to be superior to tamoxifen in overall response, TTP, and time to treatment failure. 8 Anastrozole and letrozole have now been approved in Canada and the United States as alternatives to tamoxifen in the first-line treatment of hormone-sensitive breast cancer. All three agents have advantages and disadvantages in terms of disease response, TTP, tolerability, and cost. To quantify these differences and to provide evidence for informed formulary decision making, a cost utility analysis was performed. Within the analytic time frame evaluated, the findings revealed that both anastrozole and letrozole provide additional quality adjusted progression-free survival relative to tamoxifen, and this benefit is available at an acceptable cost to the publicly funded Canadian healthcare system. The analysis also revealed modest but consistent economic advantages with letrozole over anastrozole, regardless of the type of chemotherapy offered at disease progression and with variations in tumor response rates and cost. The primary driver behind this finding was the slightly longer TTP with letrozole relative to tamoxifen, which translated to fewer patients requiring chemotherapy for progressive disease. The economic benefits became more evident if single-agent chemotherapy with All estimates were rounded to the nearest hundred. * Converted from days in Table 5 to years. † Average cost divided by the quality-adjusted progression-free benefit. ‡ Difference in cost relative to tamoxifen divided by difference in quality adjusted progression-free benefit.
expensive drugs such as paclitaxel or docetaxel were offered to nonresponders. Costly chemotherapy would be delayed in a slightly higher number of patients treated with letrozole than with anastrozole. Given the findings of the current study and the randomized superiority trial, letrozole would be considered the hormonal treatment of choice in postmenopausal women with advanced breast cancer. These conclusions may have important implications with respect to healthcare policy in the management of patients. Both of the aromatase inhibitors provide additional quality-adjusted progression-free survival benefits relative to tamoxifen. In Canada, anastrozole and letrozole have the same drug acquisition cost, both eightfold higher than tamoxifen. However, as was suggested by the cost-utility analysis, letrozole as a formulary alternative to tamoxifen would result in a modest increase in overall treatment costs for the associated progression-free survival benefit. A similar conclusion can also be drawn with anastrozole.
There are a number of limitations in the current analysis that have to be addressed. Even though the clinical data for the decision model was abstracted from randomized trials, none of the studies directly compared anastrozole to letrozole. Therefore, the comparisons should only be made against tamoxifen. Another drawback to the decision model was the failure to consider second-line hormonal therapy for nonresponding patients without life-threatening metastases. However, limited crossover data suggest that response rates between second-line tamoxifen and the aromatase inhibitors are comparable. 9 Hence, the inclusion of a second-line hormonal sequence in the model would not have altered the findings of the analysis. The final limitation that should be acknowledged was that the cost of managing drug-related side effects such as thromboembolic events was not included in the analysis. This was a bias against the aromatase inhibitors, since the incidence of thromboembolic events was higher with tamoxifen. 6 -8 In conclusion, the cost-utility analysis revealed that letrozole and anastrozole are both economically acceptable alternatives to tamoxifen in the first-line treatment setting. However, given the available clinical data and the findings of the current study, letrozole would be the preferred choice.
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